355results about How to "Strong antiviral activity" patented technology

The invention relates to substituted thiophenes and processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, in particular for hepatitis C viruses.

The present invention discloses II kinds of andrographolide sulfonated derivatives with the actions of resisting bacteria, relieving inflammation and reducing fever and medicine composition containing them. They can be used for preparing freeze-dried powder, injection or oral preparation, and can be used for curing the diseases of pneumonia, bronchitis, tonsillitis and bacillary dysentery, etc.

A treatment composition for treating or preventing bovine mastitis, the treatment composition characterised in that it includes at least two components which have an isoelectric point of or above substantially 6.8 and is extracted from milk, or a milk derived substance.

The invention relates to a formula of an aquatic product composite preservative. The formula of the aquatic product composite preservative is characterized in that the aquatic product composite preservative in each liter of distilled water comprises the following components: 0.4 to 0.6 g of muramidase, 2.5 to 3.5 g of tea polyphenol, 16 to 20 g of carboxymethyl chitosan, 10 to 14 g of nisin, 25 to 35 g of potassium sorbate, 17 to 23 g of sodium alginate, 20 to 30 g of lactobacillus, 1.5 to 2.5 g of propolis extracts and 10 to 14 g of spice extracts; and the spice extracting liquid comprises the raw materials: galangal, garlic, onion, cinnamon, clove and rosemary. The aquatic product composite preservative provided by the invention is prepared by compounding biological preservatives, is safe and non-toxic, has simple preparation and application methods, prominent microbial inhibition effect and good preservation effect, can greatly prolong the shelf life of frozen aquatic products, and has important industrial value.

The invention relates to a composite natural fresh-keeping agent for cold fresh meat and application of composite natural fresh-keeping agent. The composite natural fresh-keeping agent for the cold fresh meat is characterized by comprising tea polyphenol, chitosan, nisin, natamycin, lysozyme, oregano essential oil, vitamin C, vitamin E, erythorbic acid, a spice extract and water in certain proportions by weight, wherein the spice extract is obtained by extracting ginger, garlic, cinnamon, cardamom, clove and rosemary in certain proportions by weight through ethanol extraction. The composite natural fresh-keeping agent for the cold fresh meat is prepared from biological-source raw materials by a simple preparation method, has the advantages of non-toxicity, safety, broad antibacterial spectrum and the like, is convenient to operate during using and prominent in fresh-keeping effect, and has an important industrial value.

The invention relates to an animal genetic engineering interferon compound preparation, the production method and the clinical application. The animal genetic engineering interferon compound preparation is prepared by extracting the animal peripheral blood or spleen lymphocytes, culturing, inducing by in vitro inductor, extracting the cell total RNA by Trizol, designing the specific primer, cloning the interferon gene by RT-PCR technology and connecting to the pGEM-T carrier by T-A strategy; the primer is designed again, the both ends are added with different restriction endonucleases digestion sequences, initiation codon ATG and termination codon TAA, leading peptide sequences are removed, the PCR amplification is carried out by taking the recombination T carrier as the template, so as to obtain the expression fragment of the animal interferon gene; the expression fragment is carried out with the rare codon mutation, and gel recovery target fragment is connected on the carrier of pFastBac<TM>Dual with the same double restriction endonucleases digestion after double restriction endonucleases digestion; the interferon-Alpha of an animal is cloned to multiple cloning sites under the control of Polyhedrin promoter, the interferon-Gamma of the same species animal is cloned to multiple cloning sites under the control of p10 promoter; the constructed carrier of pFastBac<TM>Dual plus interferon Alpha plus interferon Gamma are transfected to DH10Bac<TM>E.coli to carry out recombination; the constructed recombinant bacmid is extracted and purified after the blue white screening and the PCR identification, and the transfection of SF9 insect cell is carried out by a liposome method; the expression product is carried out with identification and purification; the animal genetic engineering interferon compound preparation is carried out with anti-virus activity detection and the evaluation of the clinical application effects.

Provided are synthetic peptides based on a native sequence of HIV gp41 HR2 except that the synthetic peptides have a plurality of amino acid replacements comprising (a) a helix-promoting amino acid, or (b) a combination of helix-promoting amino acids, and charged amino acids introduced to form ion pairs in the synthetic peptide; wherein the synthetic peptides demonstrate an unexpected, improved biological activity, as compared to a peptide having an amino acid sequence without the plurality of amino acid substitutions. Also provided are polynucleotides encoding synthetic peptide, and methods of using these synthetic peptides in inhibition of, or as compositions to inhibit, transmission of HIV to a target cell.

The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

The present invention concerns mono- or di-substituted indole derivatives (I) which are useful to prevent or treat dengue viral infections and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

2-Amino-6-arylthiopurine phosphonate shows no toxicity (inhibition of bone marrow cell growth, mutagenicity, etc.) but a high antiviral activity, has an oral absorbability and a high safety and can be produced in a short process. Thus, use of this compound makes it possible to provide an excellent antiviral agent which can be efficiently produced.

The invention discloses a human lysozyme-antibacterial peptide Catesbeianin-1 fusion protein, also provides a gene engineering preparation method thereof, and further provides the application of a fusion protein biological agent on preventing and curing cow mastitis. A human lysozyme and antibacterial peptide Catesbeianin-1 gene is connected with a high-efficiency eukaryotic expression vector in afusion protein form through a gene recombination mode to further enhance the antimicrobial and antiviral activity of the fusion protein so as to obtain an antimicrobial and antiviral recombined protein with higher activity, and the fusion protein is used to prevent and cure the cow mastitis so as to develop a novel medicine which has no chemical medicine residue and antibiotic residue and low medicine resistance and can be used for preventing and curing the cow mastitis,.

The invention discloses a production process of fusion expression recombinant chicken interferon alpha. The process includes the steps of: S1, according to the preference of Escherichia coli codon, conducting codon optimization on a chicken interferon alpha gene sequence published in Genebank, and artificially synthesizing the chicken interferon alpha gene; S2, according to the codon optimized chicken interferon alpha gene, designing three specific primers; S3, constructing recombinant chicken interferon alpha plasmid containing ProS2 dissolution promoting label; S4, transforming and identifying the recombinant expression plasmid; S5, conducting inducible expression of recombinant chicken interferon alpha; S6, extracting an expression product and conducting protein renaturation purification: S61, inclusion body extraction and treatment; S62, inclusion body denaturation; S63, denaturation solution renaturation; and S64, nickel column affinity purification. By means of cell cytopathic inhibition, the invention detects that the interferon has the activity of inhibiting vesicular stomatitis virus proliferation, and the activity unit reaches 7.32*10<7>UI/mg.

The invention relates to a sulfation raw lacquer polysaccharide with biological activity prepared through the steps of, (2) dissolving or suspending the raw lacquer polysaccharide in 50-100 times weight ratio of drying solvent, stiring 10-30 min at 40-100 deg. C, charging trioxide pyridine compound of 1-4 times molar weight of raw lacquer polysaccharide residue or 1:2-4:1 volumetric ratio of sulfuric chlorohydrin pyridine mixture, reacting 0.5-4 hrs, cooling down the reaction mixture through ice bath, charging ice water with 1/3-1/2 times of solvent volume, neutralizing with 5-20wt% of NaOH, dialyzing in distilled water, subjecting the dialysate to vacuum distillation concentration at 30-70 deg. C, settling with anhydrous alcohol, and vacuum drying with P2O5.

The invention relates to a biological-source nutritional preservative for seafood. The biological-source nutritional preservative is characterized in that each liter of the distilled water of the biological-source nutritional preservative contains 0.4-0.6g of lysozyme, 2.5-3.5g of tea polyphenols, 20-28g of carboxymethyl chitosan, 10-14g of nisin, 17-23g of sodium alginate, 20-30g of lactobacillus, 1.5-2.5g of propolis extract and 10-14g of spice extract, wherein the spice extract is made of rhizoma galangae, garlic, onion, cinnamon, clove and rosemary. The biological-source nutritional preservative has the advantages that the biological-source nutritional preservative is compound by biological preservatives and is safe, nontoxic, simple in preparation and application method, outstanding in microorganism inhibition effect, good in preservation effect, capable of greatly prolonging the shelf life of the seafood and high in industry value.

The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus).

Novel glycopeptide antibiotic derivatives, processes for their preparation, their use as a medicine, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections are provided. The present invention relates to the use of glycopeptide antibiotics and their semisynthetic derivatives to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections of subjects, more in particular infections with viruses belonging to Retroviridae, Herpes viridae, Flaviviridae and the Coronaviridae, like HIV (human immunodeficiency virus), HCV (hepatitis C virus), BVDV (bovine viral diarrhoea virus), SARS (severe acute respiratory syndrome) causing virus, FCV (feline coronavirus), HSV (herpes simplex virus), VZV (varicella zoster virus) and CMV (cytomegalovirus).

The invention discloses a charge modified lactoferrin and carrageenin combination medicine which comprises 0.01 part by weight of lactoferrin, 1.5 parts by weight of carrageenin, 5 parts by weight of carbomer, 50 parts by weight of glycerol and 0.1 part by weight of ethylparaben. The combination medicine is one of a gel, a suppository and a dressing. The combination medicine disclosed by the invention can be used for preventing and treating female human papilloma virus infection as well as preventing and treating female gynecological gram-negative bacterium infection.